See more : RLH Properties, S.A.B. de C.V. (RLHPF) Income Statement Analysis – Financial Results
Complete financial analysis of Vyant Bio, Inc. (VYNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vyant Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shanxi Changcheng Microlight Equipment Co. Ltd. (8286.HK) Income Statement Analysis – Financial Results
- Iconix Brand Group, Inc. (ICON) Income Statement Analysis – Financial Results
- Mantex AB (publ) (MANTEX.ST) Income Statement Analysis – Financial Results
- ABCO Energy, Inc. (ABCE) Income Statement Analysis – Financial Results
- Sanix Incorporated (4651.T) Income Statement Analysis – Financial Results
Vyant Bio, Inc. (VYNT)
About Vyant Bio, Inc.
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 666.00K | 1.15M | 867.00K | 7.31M | 27.47M | 29.12M | 27.05M | 18.04M | 10.20M | 6.61M | 4.30M | 3.02M | 2.52M | 1.67M |
| Cost of Revenue | 1.01M | 1.85M | 1.10M | 3.70M | 18.72M | 18.07M | 17.10M | 14.10M | 8.45M | 4.92M | 3.93M | 3.12M | 3.52M | 2.53M |
| Gross Profit | -342.00K | -699.00K | -234.00K | 3.60M | 8.75M | 11.05M | 9.95M | 3.94M | 1.75M | 1.69M | 372.57K | -98.00K | -994.61K | -865.93K |
| Gross Profit Ratio | -51.35% | -60.89% | -26.99% | 49.34% | 31.84% | 37.95% | 36.77% | 21.85% | 17.12% | 25.50% | 8.66% | -3.25% | -39.44% | -51.99% |
| Research & Development | 6.77M | 4.27M | 3.23M | 0.00 | 2.49M | 4.79M | 5.97M | 5.48M | 4.62M | 2.19M | 2.11M | 2.07M | 1.17M | 1.34M |
| General & Administrative | 0.00 | 0.00 | 6.60M | 5.17M | 19.18M | 19.89M | 16.03M | 14.57M | 12.37M | 6.12M | 4.50M | 4.44M | 3.45M | 1.84M |
| Selling & Marketing | 8.80M | 8.42M | 2.72M | 1.15M | 5.27M | 4.99M | 4.67M | 5.27M | 3.96M | 1.84M | 1.40M | 1.57M | 715.97K | 239.46K |
| SG&A | 8.80M | 8.42M | 2.72M | 6.32M | 24.45M | 24.88M | 20.70M | 19.84M | 16.33M | 7.96M | 5.90M | 6.01M | 4.16M | 2.08M |
| Other Expenses | 0.00 | 57.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.57M | 12.70M | 5.95M | 6.32M | 26.94M | 29.67M | 26.67M | 25.32M | 20.95M | 10.15M | 8.01M | 8.09M | 5.33M | 3.42M |
| Cost & Expenses | 16.58M | 14.54M | 7.05M | 10.02M | 45.66M | 47.74M | 43.77M | 39.42M | 29.41M | 15.07M | 11.94M | 11.20M | 8.84M | 5.95M |
| Interest Income | 0.00 | 0.00 | 0.00 | 108.00K | 21.00K | 63.00K | 23.00K | 49.00K | 73.80M | 29.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 93.00K | 0.00 | 535.00K | 1.44M | 2.12M | 2.13M | 454.00K | 344.00K | 472.82K | 2.39M | 4.70M | 1.31M | 792.42K | 2.09M |
| Depreciation & Amortization | 843.00K | 8.23M | 2.56M | 757.00K | 2.11M | 2.17M | 2.38M | 1.66M | 838.60K | 326.48K | 353.41K | 13.05K | 537.31K | 3.24K |
| EBITDA | -15.07M | -15.71M | -5.06M | -5.03M | -16.14M | -18.62M | -16.72M | -19.36M | -17.68M | -10.32M | -1.61M | -18.56M | -7.08M | -5.23M |
| EBITDA Ratio | -2,262.61% | -651.39% | -583.85% | -68.80% | -58.75% | -64.10% | -47.96% | -107.33% | -173.36% | -156.16% | -37.46% | -614.68% | -280.68% | -314.18% |
| Operating Income | -15.91M | -15.71M | -7.62M | -2.71M | -18.19M | -18.62M | -16.72M | -21.38M | -19.21M | -8.46M | -7.64M | -8.18M | -6.32M | -4.29M |
| Operating Income Ratio | -2,389.19% | -1,368.12% | -879.24% | -37.14% | -66.23% | -63.95% | -61.83% | -118.50% | -188.34% | -128.01% | -177.62% | -271.08% | -250.76% | -257.31% |
| Total Other Income/Expenses | 105.00K | -2.87M | -1.03M | -4.68M | -2.18M | -4.34M | 921.00K | 9.00K | 215.98K | -4.57M | 974.96K | -11.70M | -2.08M | -3.04M |
| Income Before Tax | -15.81M | -18.58M | -8.65M | -7.40M | -20.37M | -22.96M | -15.80M | -21.37M | -18.99M | -13.04M | -6.67M | -19.89M | -8.41M | -7.33M |
| Income Before Tax Ratio | -2,373.42% | -1,618.03% | -997.69% | -101.26% | -74.16% | -78.84% | -58.42% | -118.45% | -186.22% | -197.22% | -154.96% | -658.64% | -333.42% | -439.96% |
| Income Tax Expense | 6.88M | 27.52M | 546.00K | -512.00K | -59.00K | -2.08M | 1.38M | -1.18M | -2.35M | -663.90K | 5.68M | -10.39M | -1.29M | -950.49K |
| Net Income | -22.69M | -46.10M | -9.20M | -6.71M | -20.37M | -20.88M | -15.80M | -20.18M | -16.64M | -12.37M | -6.67M | -19.89M | -8.41M | -7.33M |
| Net Income Ratio | -3,406.91% | -4,015.24% | -1,060.67% | -91.83% | -74.16% | -71.70% | -58.42% | -111.88% | -163.18% | -187.18% | -154.96% | -658.64% | -333.42% | -439.96% |
| EPS | -3.87 | -10.19 | -18.50 | -17.40 | -111.98 | -151.58 | -149.45 | -294.00 | -264.20 | -397.81 | -278.28 | -381.45 | -350.99 | -305.94 |
| EPS Diluted | -3.87 | -10.19 | -18.50 | -17.40 | -111.98 | -151.58 | -149.45 | -293.97 | -263.85 | -396.90 | -277.98 | -381.45 | -350.61 | -305.61 |
| Weighted Avg Shares Out | 5.87M | 4.53M | 497.20K | 385.60K | 181.94K | 137.75K | 105.74K | 68.65K | 62.99K | 31.10K | 23.95K | 52.14K | 23.95K | 23.95K |
| Weighted Avg Shares Out (Dil) | 5.87M | 4.53M | 497.20K | 385.60K | 181.94K | 137.75K | 105.74K | 68.66K | 63.08K | 31.17K | 23.98K | 52.14K | 23.98K | 23.98K |
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript
Vyant Bio, Inc. (NASDAQ:VYNT ) Q2 2022 Results Earnings Conference Call August 22, 2022 4:30 PM ET Company Participants Jay Roberts - President and Chief Executive Officer Andrew LaFrence - Chief Financial Officer Robert Fremeau - Chief Scientific Officer Conference...
Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug...
Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast
CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug...
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug...
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q1 2022 Results - Earnings Call Transcript
Vyant Bio, Inc. (NASDAQ:VYNT ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Robert Fremeau - Chief Scientific Officer Conference Call Participants Ed...
Vyant Bio ends 1Q with $16.4M in cash to fund small molecule therapeutics research for neurological diseases
Vyant Bio (NASDAQ:VYNT) Inc ended its first quarter with $16.4 million after a busy three months that saw it progress the discovery of small molecule therapeutics to treat neurological diseases. In the period to March 31, 2022, the Cherry Hill, New Jersey-based company...
Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022
CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system (“CNS”) drug discovery platform combines...
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA...
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q4 2021 Results - Earnings Call Transcript
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q4 2021 Results - Earnings Call Transcript
Vyant Bio ends 2021 with $20.6M in cash as it sharpens focus on novel drug discovery
Vyant Bio (NASDAQ:VYNT) Inc ended its 2021 financial year with a beefed-up cash balance of $20.6 million to help the biotechnology company pursue its development of drugs for complex neurodevelopmental and neurodegenerative disorders. The company is focused primarily on the discovery...
Source: https://incomestatements.info
Category: Stock Reports